MedTrace Logo

Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

NCT06350890 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2025-12-29

No results posted yet for this study

Summary

The goal of this clinical study is to evaluate the efficacy and safety of Berberine Ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes, inadequately controlled with diet and exercise alone.

Conditions

  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

HTD1801

HTD1801 1000 mg administered orally BID as four capsules

DRUG

Placebo

Matching placebo administered orally BID as four capsules

Sponsors & Collaborators

  • Shenzhen HighTide Biopharmaceutical Ltd.

    collaborator UNKNOWN

  • HighTide Biopharma Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Kui Liu, MD · Shenzhen HighTide Biopharmaceutical Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-05
Primary Completion
2024-12-12
Completion
2025-08-04

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06350890 on ClinicalTrials.gov